Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study.
Zicheng HuKattria van der PloegSaborni ChakrabortyPrabhu S ArunachalamDiego A M MoriKaren B JacobsonHector BonillaJulie ParsonnetJason R AndrewsMarisa HolubarAruna SubramanianChaitan KhoslaYvonne MaldonadoHaley HedlinLauren de la ParteKathleen PressMaureen TyGene S TanCatherine BlishSaki TakahashiIsabel Rodriguez-BarraquerBryan GreenhouseAtul Janardhan ButteUpinder SinghBali PulendranTaia T WangPrasanna JagannathanPublished in: eLife (2022)
Support for the study was provided from National Institute of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) (U01 AI150741-01S1 and T32-AI052073), the Stanford's Innovative Medicines Accelerator, National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA) DP1DA046089, and anonymous donors to Stanford University. Peginterferon lambda provided by Eiger BioPharmaceuticals.